• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Monday

    1/9/23 11:20:01 AM ET
    $ARVN
    $CERS
    $CIO
    $CUTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $ARVN alert in real time by email

    Companies That Fell Through 52-Week Lows Monday

    During Monday's morning trading, 14 companies set new 52-week lows.

    Things to Consider About Today's 52-Week Lows:

    • L3Harris Technologies (NYSE:LHX) was the biggest company on a market cap basis to set a new 52-week low.
    • The smallest company by market cap to hit a new 52-week low was Nabriva Therapeutics (NASDAQ:NBRV).
    • Cutera (NASDAQ:CUTR) shares traded down 23.86% to reach its 52-week low, making it the biggest loser.
    • Nabriva Therapeutics (NASDAQ:NBRV)'s stock made the biggest reversal, trading up 0.77% shortly after dropping to a new 52-week low.

    Here is a list of stocks that set new 52-week lows on Monday:

    • L3Harris Technologies (NYSE:LHX) stock hit a new 52-week low of $200.33. The stock was down 1.31% on the session.
    • Arvinas (NASDAQ:ARVN) stock dropped to a yearly low on Monday of $27.00. Shares traded down 12.8%.
    • Cutera (NASDAQ:CUTR) shares hit a yearly low of $29.49. The stock was down 23.86% on the session.
    • Cerus (NASDAQ:CERS) shares set a new 52-week low of $3.06. The stock traded down 17.99%.
    • PMV Pharma (NASDAQ:PMVP) shares hit a yearly low of $8.08. The stock was down 3.23% on the session.
    • City Office REIT (NYSE:CIO) stock set a new 52-week low of $8.03 on Monday, moving down 1.72%.
    • PIMCO California (NYSE:PCQ) shares reached a new 52-week low of $12.20 on Monday morning, moving down 1.48%.
    • DLH Hldgs (NASDAQ:DLHC) stock hit a new 52-week low of $10.80. The stock was down 9.24% on the session.
    • Peak Bio (NASDAQ:PKBO) shares set a new yearly low of $2.84 this morning. The stock was down 11.93% on the session.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ARVN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARVN
    $CERS
    $CIO
    $CUTR

    CompanyDatePrice TargetRatingAnalyst
    Arvinas Inc.
    $ARVN
    10/15/2025$6.00Neutral → Sell
    Goldman
    Arvinas Inc.
    $ARVN
    9/24/2025$10.00Buy → Neutral
    BofA Securities
    Arvinas Inc.
    $ARVN
    9/17/2025$16.00Overweight
    Barclays
    Arvinas Inc.
    $ARVN
    6/2/2025$9.00Outperform → Market Perform
    Leerink Partners
    Arvinas Inc.
    $ARVN
    5/5/2025$11.00Buy → Hold
    Truist
    Arvinas Inc.
    $ARVN
    5/2/2025$10.00Buy → Hold
    Jefferies
    Arvinas Inc.
    $ARVN
    5/2/2025Buy → Hold
    TD Cowen
    L3Harris Technologies Inc.
    $LHX
    4/11/2025$263.00Sell → Buy
    Goldman
    More analyst ratings

    $ARVN
    $CERS
    $CIO
    $CUTR
    SEC Filings

    View All

    SEC Form 10-Q filed by Cerus Corporation

    10-Q - CERUS CORP (0001020214) (Filer)

    11/6/25 5:01:17 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CERUS CORP (0001020214) (Filer)

    11/6/25 4:03:44 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form 10-Q filed by Arvinas Inc.

    10-Q - ARVINAS, INC. (0001655759) (Filer)

    11/5/25 4:06:28 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pres., Integrated Mission Sys. Rambeau Jon converted options into 4,147 shares and covered exercise/tax liability with 1,632 shares, increasing direct ownership by 87% to 5,415 units (SEC Form 4)

    4 - L3HARRIS TECHNOLOGIES, INC. /DE/ (0000202058) (Issuer)

    11/4/25 4:36:14 PM ET
    $LHX
    Industrial Machinery/Components
    Industrials

    President and CEO Mack David Henry exercised 220,643 shares at a strike of $1.37, increasing direct ownership by 96% to 451,109 units (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    10/29/25 4:11:57 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Orbimed Advisors Llc sold $1,520,000 worth of shares (1,000,000 units at $1.52) (SEC Form 4)

    4 - PMV Pharmaceuticals, Inc. (0001699382) (Issuer)

    10/27/25 5:19:23 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Arvinas downgraded by Goldman with a new price target

    Goldman downgraded Arvinas from Neutral to Sell and set a new price target of $6.00

    10/15/25 8:13:39 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arvinas downgraded by BofA Securities with a new price target

    BofA Securities downgraded Arvinas from Buy to Neutral and set a new price target of $10.00

    9/24/25 7:54:47 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Arvinas with a new price target

    Barclays resumed coverage of Arvinas with a rating of Overweight and set a new price target of $16.00

    9/17/25 7:57:56 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Mink Brook Asset Management Llc bought $1,111 worth of shares (202 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    10/21/25 6:01:18 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    Large owner Mink Brook Asset Management Llc bought $4,455 worth of shares (810 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    10/17/25 4:31:45 PM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    Large owner Mink Brook Asset Management Llc bought $73,018 worth of shares (13,276 units at $5.50) (SEC Form 4)

    4 - DLH Holdings Corp. (0000785557) (Issuer)

    10/8/25 8:20:56 AM ET
    $DLHC
    Professional Services
    Consumer Discretionary

    $ARVN
    $CERS
    $CIO
    $CUTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

    Third Quarter Total Revenue up 19% to $60.2 Million; Record Product Revenue of $52.7 Million, Up 15% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $202 Million - $204 Million Cerus Corporation (NASDAQ:CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. "We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System. Fu

    11/6/25 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    – Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson's disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer – – Presented preclinical data from ARV-027 demonstrating robust degradation of polyQ-AR in muscle, supporting further evaluation as a potentially disease-modifying therapy in SBMA – – Announced agreement with Pfizer to jointly select a third party for the commercialization and potential further development of vepdegestrant – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Nov. 05, 2025 (GLOBE NEWSWIRE)

    11/5/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pimco Closed-End Funds Declare Monthly Common Share Distributions

    NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Boards of Trustees/Directors of the PIMCO closed-end funds below (each, a "Fund" and, collectively, the "Funds") have declared a monthly distribution for each Fund's common shares as summarized below. For the following Funds, the distributions are payable on December 1, 2025 to shareholders of record on November 14, 2025, with an ex-dividend date of November 14, 2025:    Monthly Distribution Per ShareFundNYSE SymbolAmountChange From Previous MonthPercentage Change From Previous MonthPIMCO Corporate & Income Strategy Fund(NYSE:PCN)$0.112500--PIMCO Corporate & Income Opportunity Fund(NYSE:PTY)$0.118800--PIMCO Global StocksPLUS® & Income

    11/3/25 4:20:00 PM ET
    $PAXS
    $PCM
    $PCN
    Investment Managers
    Finance
    Trusts Except Educational Religious and Charitable
    Finance/Investors Services

    $ARVN
    $CERS
    $CIO
    $CUTR
    Leadership Updates

    Live Leadership Updates

    View All

    Oksenholt Capital Slams City Office REIT's "Lowball" Elliott Capital Offer, Calls for New Leadership and Strategic Restructuring

      Oksenholt Capital Management LLC ("Oksenholt Capital") today announced that its Chief Executive Officer, Jon Oksenholt, has sent a formal letter to the Chairman of the Board of City Office REIT, Inc. (NYSE:CIO), outlining serious concerns about the company's leadership, performance, and opposition to the proposed merger with affiliates of Elliott Capital. The letter identified several issues related to City Office REIT, Inc.'s ("CIO") current management and voiced opposition to the pending proposed acquisition/merger with affiliates of Elliott Capital. Affiliates of Oksenholt Capital Management LLC have Acquired Several Hundred Thousand Shares of City Office REIT, Inc., Comprising

    10/7/25 6:00:00 PM ET
    $CIO
    Real Estate Investment Trusts
    Real Estate

    Global Threat Surge Leads to $2.7T Defense Spending Boom and Institutional Rush

    Equity Insider News Commentary Issued on behalf of VisionWave Holdings, Inc. VANCOUVER, BC, Sept. 26, 2025 /PRNewswire/ -- Global military spending hit a record $2.7 trillion in 2024, marking a 9.4% surge that represents the steepest year-over-year increase in at least three decades as nations respond to "intensifying wars and rising geopolitical tensions worldwide," according to UN report[1]. NATO's updated defense expenditure data released in August confirms all 32 allies are expected to meet the 2% GDP spending target this year, while the alliance's commitment to reach 5% of GDP by 2035 creates unprecedented demand for advanced military technologies and platforms[2]. This defense spending

    9/26/25 10:30:00 AM ET
    $GD
    $LHX
    $LMT
    Marine Transportation
    Industrials
    Industrial Machinery/Components
    Military/Government/Technical

    Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

    – John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of Directors – – Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, an

    7/9/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by City Office REIT Inc.

    SC 13G/A - City Office REIT, Inc. (0001593222) (Subject)

    11/14/24 4:05:11 PM ET
    $CIO
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Arvinas Inc.

    SC 13G/A - ARVINAS, INC. (0001655759) (Subject)

    11/14/24 1:22:38 PM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARVN
    $CERS
    $CIO
    $CUTR
    Financials

    Live finance-specific insights

    View All

    Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

    Third Quarter Total Revenue up 19% to $60.2 Million; Record Product Revenue of $52.7 Million, Up 15% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $202 Million - $204 Million Cerus Corporation (NASDAQ:CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. "We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System. Fu

    11/6/25 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    – Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson's disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer – – Presented preclinical data from ARV-027 demonstrating robust degradation of polyQ-AR in muscle, supporting further evaluation as a potentially disease-modifying therapy in SBMA – – Announced agreement with Pfizer to jointly select a third party for the commercialization and potential further development of vepdegestrant – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Nov. 05, 2025 (GLOBE NEWSWIRE)

    11/5/25 7:00:00 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    L3Harris Technologies Reports Strong Third Quarter 2025 Results, Increases 2025 Guidance

    L3Harris Technologies (NYSE:LHX) reports third quarter 2025 results. Highlights* Orders of $6.7 billion; book-to-bill of 1.2x Revenue of $5.7 billion, up 7% versus prior year, and 10% organically Operating margin of 11.0%; Adjusted segment operating margin of 15.9% Diluted EPS of $2.46; Non-GAAP diluted EPS of $2.70, up 10% versus prior year 2025 guidance increased on strong performance and higher expectations "We delivered another strong quarter, with robust organic revenue growth of 10%, reflecting our commitment to operational excellence and relentless focus on execution as drivers of profitable growth. We are driving sustained performance, marking our eighth consecut

    10/30/25 6:55:00 AM ET
    $LHX
    Industrial Machinery/Components
    Industrials